Final Information Book Introduction of CVRF
| Date | Time | Place | Session / Title | Role |
| April 27 | 5:00 PM - 6:10 PM | Presentation Theater 1, Level 1 | Valves | Panelist |
| April 27 | 5:16 PM - 5:24 PM | Presentation Theater 1, Level 1 | Valves Durability of Transcatheter Aortic Valves: An Update |
Lecturer |
| April 28 | 7:00 AM - 8:00 AM | Presentation Theater 2, Level 1 | Antithrombotics in High-Risk Patients | Panelist |
| April 28 | 7:32 AM - 7:40 AM | Presentation Theater 2, Level 1 | Antithrombotics in High-Risk Patients Optimal Antithrombotics for Complex Patients: Different Drugs, Dosing, or Duration? |
Lecturer |
| April 28 | 2:00 PM - 3:06 PM | Presentation Theater 1, Level 1 | Antithrombotics | Panelist |
| April 28 | 2:37 PM - 2:45 PM | Presentation Theater 1, Level 1 | Antithrombotics Atrial Fibrillation and ACS/PCI: Chains of RCTs up to AUGUSTUS - Enough Evidence or More? |
Lecturer |
| April 28 | 3:20 PM - 3:40 PM | Interview Lounge, Level 2 | Antithrombotics | Interviewee |
| April 29 | 7:00 AM - 8:10 AM | Presentation Theater 1, Level 1 | New DES and Stent Failure | Panelist |
| April 29 | 8:30 AM - 9:45 AM | Presentation Theater 1, Level 1 | Spotlights of Major Clinical Studies with Expert Commentary | Discussant |
| April 29 | 9:38 AM - 9:45 AM | Presentation Theater 1, Level 1 | Spotlights of Major Clinical Studies with Expert Commentary Discussion: A Journey of PCSK9 Inhibitors: From Genetics To Clinics |
Discussant |
